Barinthus Biotherapeutics Initiates First-in-Human Trial of VTP-1000 for Celiac Disease
Barinthus Biotherapeutics is conducting a first-in-human trial to evaluate the safety and tolerability of VTP-1000 in adults with celiac disease.
Asset / Drug
Drug and asset intelligence for VTP-1000 with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.